Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd banner

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SGX:T14

Watchlist Manager
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Logo
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SGX:T14
Watchlist
Price: 3.2 USD -0.31% Market Closed
Market Cap: $4.6B

T14's latest stock split occurred on Jun 30, 2010

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

The adjusted shares began trading on Jun 30, 2010. This was the only stock split in T14's history.

Last Splits:
Jun 30, 2010
2-for-1
Pre-Split Price
N/A
Post-Split Price
0.0852
Before
After
Last Splits:
Jun 30, 2010
2-for-1

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Stock Splits History

T14 Stock Splits Timeline
Jun 30, 2010
Jun 30, 2010
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
0.0852
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 24, 2026
Cue Biopharma Inc
NASDAQ:CUE
1-for-30
/30
0.5542 16.626 USD 17.695 17.695 USD
Apr 24, 2026
Medical Data Vision Co Ltd
TSE:3902
2-for-7253607
/3626803.5
1684 1684 JPY N/A
Apr 24, 2026
E
ESGL Holdings Ltd
NASDAQ:ESGL
1-for-3
/3
2.35 7.05 USD 2.93 2.93 USD
Apr 24, 2026
Metro Mining Ltd
ASX:MMI
1-for-20
/20
0.067 1.34 AUD 1.3 1.3 AUD
Apr 24, 2026
L
La Comer SAB de CV
OTC:LCMRF
115-for-114
x1.0087719298246
2.4715 2.4341 USD 2.45 2.45 USD
Load More

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Glance View

Market Cap
4.6B USD
Industry
Pharmaceuticals

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd, rooted in the rich tapestry of traditional Chinese medicine, has carved out a substantial presence in the pharmaceutical industry. Established in a region known for its deep cultural heritage in holistic healing, the company seamlessly weaves ancient practices with modern scientific advancements. At the core of its operations, Da Ren Tang specializes in the research, development, production, and distribution of traditional Chinese medicine and pharmaceuticals. Beyond just leveraging ancient recipes, the company invests significantly in cutting-edge research to validate and enhance the efficacy of its formulations, gaining trust not only domestically but also in international markets. This blending of tradition and innovation enables Da Ren Tang to capture a diverse customer base, ranging from individuals seeking natural remedies to medical institutions incorporating holistic approaches into patient care. The economic engine of Da Ren Tang powers through a multi-faceted monetization strategy. It manufactures a broad portfolio of pharmaceutical products, including patented Chinese medicines and active pharmaceutical ingredients (APIs), which are distributed through a well-established network of pharmacies and healthcare providers. Additionally, the company has embraced the digital era by exploring e-commerce platforms, thereby expanding its reach and accessibility to tech-savvy consumers globally. By maintaining stringent quality controls and adopting sustainable practices in its production processes, Da Ren Tang not only enhances its reputation but also adheres to evolving regulatory standards worldwide. Such strategic positioning allows the company to capitalize on the growing global interest in traditional medicines, contributing significantly to its revenue streams and reinforcing its status as a prominent player in the pharmaceutical landscape.

T14 Intrinsic Value
2.22 USD
Overvaluation 31%
Intrinsic Value
Price $3.2
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett